Plant Name: Lophophora williamsii
Taxonomic Information:
Plant ID: NPO13613
Plant Latin Name: Lophophora williamsii
Taxonomy Genus: Lophophora
Taxonomy Family: Cactaceae
Plant External Links:
NCBI TaxonomyDB:
130138
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
China; MexicoTraditional Medicine System:
TCMGeographical Distribution:
China; Mexico
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR2B; HTR2A; HTR2C; | |
| ACHE; | |
| ALDH1A1; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP3A4; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 2.913E-10 | 6.344E-06 | HTR2A, HTR2B, HTR2C |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 4.803E-09 | 1.743E-05 | HTR2A, HTR2B, HTR2C |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 5.879E-08 | 1.067E-04 | HTR2A, HTR2B, HTR2C |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 5.879E-08 | 1.067E-04 | HTR2A, HTR2B, HTR2C |
| BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 1.126E-07 | 1.751E-04 | HTR2A, HTR2C |
| MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 1.126E-07 | 1.751E-04 | HTR2A, HTR2C |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 2.505E-07 | 3.409E-04 | ACHE, ALDH1A1, CYP3A4, HTR2A, HTR2C |
| BP | GO:0051179; localization | GO:0051209; release of sequestered calcium ion into cytosol | 4.108E-07 | 4.709E-04 | HTR2A, HTR2B, HTR2C |
| CC | GO:0045202; synapse | GO:0045202; synapse | 3.625E-03 | 4.007E-01 | ACHE, HTR2B |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.085E-02 | 7.569E-01 | HTR2A, HTR2B, HTR2C |
| CC | GO:0016020; membrane | GO:0005901; caveola | 2.545E-02 | 1.000E+00 | HTR2A |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.937E-06 | 3.924E-05 | HTR2B, HTR2C, HTR2A |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 2.844E-06 | 3.924E-05 | HTR2B, HTR2C, HTR2A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 5.887E-06 | 3.924E-05 | HTR2B, HTR2C, HTR2A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 2.444E-05 | 1.222E-04 | HTR2B, HTR2C, HTR2A |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 8.828E-05 | 3.531E-04 | HTR2B, HTR2C, HTR2A |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.161E-04 | 7.204E-04 | ALDH1A1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 1.599E-02 | 3.826E-02 | CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.011E-02 | 2.888E-02 | CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.391E-02 | 3.826E-02 | CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.013E-02 | 3.826E-02 | CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2A; HTR2C; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C; |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HTR2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR2B; HTR2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; HTR2C; |
| NA: NA | Primary insomnia | NA | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | HTR2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2A; HTR2B; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B; |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR2C; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| NA: NA | Addiction | NA | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2A; HTR2C; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR2A; HTR2C; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
